metastatic Ovarian carcinoma (DBCOND0022585)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Doxorubicin	A medication used to treat various cancers, including AIDS-associated Kaposi's Sarcoma and metastatic cancers.	DNA topoisomerase 2-alphatarget DNAtarget Cytochrome P450 3A4enzyme Cytochrome P450 2D6enzyme Cytochrome P450 2B6enzyme ATP-dependent translocase ABCB1transporter ATP-binding cassette sub-family C member 3transporter ATP-binding cassette sub-family C member 6transporter Multidrug resistance-associated protein 1transporter ATP-binding cassette sub-family C member 10transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Bile salt export pumptransporter Solute carrier family 22 member 16transporter Mitochondrial potassium channel ATP-binding subunittransporter Cytochrome P450 1B1enzyme Carbonyl reductase [NADPH] 1enzyme Carbonyl reductase [NADPH] 3enzyme Aldo-keto reductase family 1 member A1enzyme Aldo-keto reductase family 1 member C3enzyme NAD(P)H dehydrogenase [quinone] 1enzyme Xanthine dehydrogenase/oxidaseenzyme Nitric oxide synthase 3enzyme Nitric oxide synthase, inducibleenzyme Nitric oxide synthase 1enzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrialenzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrialenzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrialenzyme NADPH--cytochrome P450 reductaseenzyme RalA-binding protein 1transporter ATP-binding cassette sub-family C member 2transporter Albumincarrier Nucleolar and coiled-body phosphoprotein 1target DNA topoisomerase 1target DNA topoisomerase 2-betatarget Aldo-keto reductase family 1 member B1enzyme Aldo-keto reductase family 1 member B10enzyme Aldo-keto reductase family 1 member C4enzyme Telomerase reverse transcriptasetarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04514484	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Cabozantinib Nivolumab	treatment	1	active_not_recruiting
NCT04550494	Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations	Talazoparib	treatment	2	recruiting
NCT06264921	A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors	No drug interventions	treatment	1	recruiting
NCT05092373	Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax	Albumin human Atezolizumab Cabozantinib Paclitaxel	treatment	1	recruiting
NCT04811703	Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer	No drug interventions	treatment	1	recruiting
NCT06586957	A Study with NKT3964 for Adults with Advanced/Metastatic Solid Tumors	No drug interventions	treatment	1	not_yet_recruiting
NCT05075993	Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors	Bevacizumab Cyclophosphamide Exlinkibart Paclitaxel	treatment	1	recruiting
NCT02298959	Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer	Aflibercept Pembrolizumab	treatment	1	active_not_recruiting
NCT02650986	Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1	Cyclophosphamide Decitabine Lifileucel	treatment	1 / 2	active_not_recruiting
NCT04498520	Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer	Abexinostat Fulvestrant Palbociclib	treatment	1	withdrawn
NCT04703920	Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer	Belinostat Talazoparib	treatment	1	recruiting
NCT04329494	PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer	Chloride ion Cisplatin Daunorubicin Doxorubicin Fluorouracil Irinotecan Leucovorin Mitomycin Oxaliplatin Platinum	treatment	1	recruiting
NCT03987555	Paclitaxel Therapeutic Drug Monitoring in Cancer Patients	No drug interventions	Not Available	Not Available	recruiting
NCT02627443	Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Berzosertib Carboplatin Gemcitabine	treatment	1	active_not_recruiting
NCT03610490	Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma	Cyclophosphamide Fludarabine Human interleukin-2 Lifileucel Teceleukin	treatment	2	terminated
NCT05733000	CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors	Devimistat Fluorouracil Gemcitabine Hydroxychloroquine Lipoic acid	treatment	2	recruiting
NCT03508570	Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis	Ipilimumab Nivolumab	treatment	1	active_not_recruiting
NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	Dostarlimab Niraparib	treatment	1	recruiting
NCT05759923	First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours	No drug interventions	treatment	1	recruiting